A newly approved pacemaker is undergoing ongoing surveillance for concerns. Which step of device development does this represent?

A newly approved pacemaker is undergoing ongoing surveillance for concerns. Which step of device development does this represent?

• A. Pre-market evaluation
• B. FDA post-market safety monitoring
• C. Clinical trial initiation
• D. Manufacturing scale-up

Answer: (B)

Ongoing surveillance after a device is approved is about safety in the real world. This is FDA post-market safety monitoring. Once a pacemaker hits the market, regulators require continuous collection and review of safety data, reports of adverse events, and real-world performance to detect rare or long-term problems not seen in pre-approval trials. This step ensures the benefit–risk balance remains favorable over time. It’s different from pre-market evaluation (the testing and studies done before approval), initiating clinical trials (starting the research), or manufacturing scale-up (ramping up production).

Ongoing surveillance after a device is approved is about safety in the real world. This is FDA post-market safety monitoring. Once a pacemaker hits the market, regulators require continuous collection and review of safety data, reports of adverse events, and real-world performance to detect rare or long-term problems not seen in pre-approval trials. This step ensures the benefit–risk balance remains favorable over time. It’s different from pre-market evaluation (the testing and studies done before approval), initiating clinical trials (starting the research), or manufacturing scale-up (ramping up production).